About Us

What we do
We are focused on addressing expensive treatment of diabetes and lack of insulin access globally.

rBIO is a biotech company looking to bring pharmaceutical supply chains back to the USA by harnessing the power of recombinant DNA technologies. Single-celled organisms like yeast, bacteria, and algae represent the next manufacturing boom of biological products as the secrets of genetics continue to be unlocked. This coronavirus pandemic has highlighted gaps in the healthcare market and shown that America cannot rely on other countries to control the production of life-saving medication that its citizens rely on. Not only does rBIO have the potential to generate significant revenues from the sale of synthetic biological products, it is in national security interests to have these supply chains back on domestic soil.


To date, rBIO has secured lab space, purchased equipment, and designed 7 new strains of E. Coli bacteria to produce and express synthetic insulin, human growth hormone (HGH), erythropoietin (EPO), and follicle stimulating hormone (FSH). During lab testing of the protocols and procedures, yields will be determined and will be used as an important metric as the company grows into larger scale operations. Many other strains of synthetic bacteria could be designed to produce a host of other biological products, but insulin represents the best molecule to launch with due to the high prevalence and growth of type 2 diabetes here in the United States and worldwide.